Payment overview · 2025
General Payments
$388.48
18 reported records · 11 companies
Healthcare provider profile · identity verified
Steven Douglas Maness, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GRESHAM, OR · NPI 1700872785
Verified facts
What the public records show
CMS Open Payments records show Steven Douglas Maness, M.D. received $388.48 in general payments during 2025 across 18 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $96.67 | 24.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $76.59 | 19.7% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.66 | 17.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.41 | 6.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.20 | 6.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.54 | 6.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.96 | 4.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.41 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.50 | 3.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.91 | 3.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.63 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $388.48 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $96.67 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $66.66 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.25 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.25 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $27.54 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 205 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
205 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1033 | 278 |
| Losartan Potassium | Losartan Potassium | 615 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 607 | 158 |
| Lisinopril | Lisinopril | 506 | 136 |
| Metoprolol Succinate | Metoprolol Succinate | 479 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 91 |
| Duloxetine Hcl | Duloxetine Hcl | 285 | 72 |
| Metformin Hcl | Metformin Hcl | 271 | 84 |
| Gabapentin | Gabapentin | 266 | 66 |
| Omeprazole | Omeprazole | 213 | 55 |
| Eliquis | Apixaban | 205 | 43 |
| Jardiance | Empagliflozin | 198 | 44 |
| Allopurinol | Allopurinol | 195 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 54 |
| Trazodone Hcl | Trazodone Hcl | 182 | 43 |
| Sertraline Hcl | Sertraline Hcl | 154 | 32 |
| Furosemide | Furosemide | 128 | 31 |
| Torsemide | Torsemide | 125 | 36 |
| Carvedilol | Carvedilol | 121 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 35 |
| Spironolactone | Spironolactone | 111 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 27 |
| Alendronate Sodium | Alendronate Sodium | 101 | 31 |
| Bupropion Xl | Bupropion Hcl | 101 | 25 |
| Simvastatin | Simvastatin | 96 | 26 |
| Potassium Chloride | Potassium Chloride | 95 | 25 |
| Prednisone | Prednisone | 91 | 56 |
| Ozempic | Semaglutide | 85 | 15 |
| Mirtazapine | Mirtazapine | 84 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 13 |
| Ezetimibe | Ezetimibe | 66 | 18 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 65 | 65 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 16 |
| Warfarin Sodium | Warfarin Sodium | 57 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 52 | 48 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | 13 |
| Finasteride | Finasteride | 47 | 13 |
| Celecoxib | Celecoxib | 44 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | suppressed |
| Acyclovir | Acyclovir | 43 | 13 |
| Hydrocortisone | Hydrocortisone | 41 | 29 |
| Mupirocin | Mupirocin | 41 | 32 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 40 | 39 |
| Famotidine | Famotidine | 40 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | 11 |
| Azithromycin | Azithromycin | 38 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Rybelsus | Semaglutide | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 29 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Famciclovir | Famciclovir | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Cefdinir | Cefdinir | 25 | 24 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Testosterone | Testosterone | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 22 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | 11 |
| Alprazolam | Alprazolam | 17 | 11 |
| Digoxin | Digoxin | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $388.48 · 18 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | ABRYSVO, AUSTEDO XR, COMIRNATY, ELIQUIS, NURTEC ODT, PREVNAR 20, PROCLAIM, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, Wegovy, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error